Dr. Reddy's Laboratories Limited ( RDY ) Nowojorska Giełda Papierów Wartościowych

Cena: 15.32 ( -1.13% )

Aktualizacja 06-26 21:59
Nowojorska Giełda Papierów Wartościowych
Branża: Drug Manufacturers - Specialty & Generic
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - Specialty & Generic
Zatrudnienie: 27 048
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 100%
Ilość akcji: 166 505 966
Debiut giełdowy: 2001-04-11
WWW: https://www.drreddys.com
CEO: Mr. Erez Israeli M.B.A.
Adres: 8-2-337, Road No. 3
Siedziba: 500034 Hyderabad
ISIN: US2561352038
Opis firmy:

Dr Reddy's Laboratories Limited, wraz z spółkami zależnymi, działa jako zintegrowana firma farmaceutyczna na całym świecie. Działa poprzez globalne generyczne usługi farmaceutyczne i składniki aktywne (PSAI), zastrzeżone produkty i inne segmenty. Globalny segment generyczny firmy produkuje i sprzedaje receptę na receptę oraz bez recepty gotowe produkty farmaceutyczne, które są sprzedawane pod marką lub jako ogólne gotowe dawki z terapeutyczną równoważnością markowych preparatów. Ten segment angażuje się również w działalność biologiczną. Segment PSAI produkuje i sprzedaje aktywne składniki i pośredniki farmaceutyczne, które są głównymi składnikami gotowych produktów farmaceutycznych. Ten segment świadczy również usługi badawcze kontraktów; oraz produkuje i sprzedaje aktywne składniki farmaceutyczne i sterydy zgodnie z konkretnymi wymaganiami klientów. Jego zastrzeżony segment produktów koncentruje się na badaniach i rozwoju zróżnicowanych formuł. Inne segment angażuje się w opracowywanie terapii w dziedzinie onkologii i stanu zapalnego. Kategorie terapeutyczne obejmują przede wszystkim żołądek żołądkowo-jelitowy, sercowo-naczyniowy, przeciwcukrzycowy, dermatologii, onkologii, oddechowej, stomatologii, urologii i nefrologii. Firma ma umowę o współpracy, licencji i opcji z Curis, Inc. w celu odkrycia, rozwijania i komercjalizacji antagonistów małych cząsteczek w celu uzyskania celów immuno-onkologii i precyzyjnych onkologii. Dr Reddy's Laboratories Limited został włączony w 1984 roku i ma siedzibę w Hyderabad w Indiach.

Wskaźniki finansowe
Kapitalizacja (USD) 12 752 223 307
Aktywa: 465 955 000 000
Cena: 15.32
Wskaźnik Altman Z-Score: 2.4
Umiarkowany (ryzyko bankructwa średnie)
Dywidenda: 0
P/E: 19.6
Ilość akcji w obrocie: 100%
Średni wolumen: 2 059 329
Ilość akcji 832 118 976
Wskaźniki finansowe
Przychody TTM 299 867 000 000
Zobowiązania: 156 672 000 000
Przedział 52 tyg.: 12.26 - 16.892
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: 0.8
P/E branży: 21.3
Beta: 0.328
Raport okresowy: 2025-07-25
WWW: https://www.drreddys.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Gunupati Venkateswara Prasad B.E. Co-Chairman, MD & Member of Management Council 2 224 369 1960
Mr. Kallam Satish Reddy B.Tech., M.S. Chairman of the Board & Member of the Management Council 1 387 186 1967
Mr. Patrick Aghanian B.A., M.B.A. Chief Executive Officer of European Generics & Member of Management Council 0 1965
Mr. Sanjay Sharma B.Tech. Executive Vice President, Global Head of Global Manufacturing & Member of Management Council 0 1968
Mr. Parag Agarwal Chief Financial Officer & Member of Management Council 0 1966
Ms. Archana Bhaskar B.Sc., M.B.A. EVice President, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council 0 1967
Mr. Krishna K. Venkatesh B.Pharma M.S. Global Head of Quality and Pharmacovigilance & Member of the Management Council 0 1973
Mr. Venkata Ramana Motupalli M.B.A. Chief Executive Officer of Branded Markets - India & Emerging Countries and Member of Management Council 0 1969
Mr. Erez Israeli M.B.A. Chief Executive Officer & Member of the Management Council 0 1968
Mr. Deepak Sapra M.B.A. Chief Executive Officer of API & Services & Member of Management Council 0 1975
Wiadomości dla Dr. Reddy's Laboratories Limited
Tytuł Treść Źródło Aktualizacja Link
Dr. Reddy's Continues To Be A Good Buy At Current Valuation I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth. seekingalpha.com 2025-05-15 15:47:57 Czytaj oryginał (ang.)
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales. zacks.com 2025-05-12 14:20:42 Czytaj oryginał (ang.)
Generics won't be affected by Trump's pricing policy, says Dr. Reddy's Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans to expand its diabetes and obesity drug offerings amid increasing competition. youtube.com 2025-05-12 07:51:22 Czytaj oryginał (ang.)
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Richa Periwal - Head, IR and Analytics Erez Israeli - CEO M V Narasimham - CFO Conference Call Participants Neha Manpuria - Bank of America Kunal Dhamesha - Macquarie Group Madhav Marda - Fidelity Amey Chalke - JM Financial Bino Pathiparampil - Elara Capital Krishnendu Saha - Quantum Mutual Fund Tushar Manudhane - Motilal Oswal Abdulkader Puranwala - ICICI Securities Surya Patra - PhillipCapital Shashank Krishnakumar - Emkay Global Shrikant Akolkar - Nuvama Wealth Saion Mukherjee - Nomura Operator Ladies and gentlemen, good evening, and welcome to Quarter Four and Full Year FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. [Operator Instructions] I now hand the conference over to Ms. seekingalpha.com 2025-05-09 22:03:02 Czytaj oryginał (ang.)
Dr. Reddy's Q4 & Full Year FY25 Financial Results HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025. businesswire.com 2025-05-09 18:53:00 Czytaj oryginał (ang.)
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia. zacks.com 2025-03-31 14:31:49 Czytaj oryginał (ang.)
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar. prnewswire.com 2025-03-27 13:47:00 Czytaj oryginał (ang.)
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review. zacks.com 2025-03-19 14:16:05 Czytaj oryginał (ang.)
Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #AVT03--Alvotech and Dr. Reddy's announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®. businesswire.com 2025-03-18 10:35:00 Czytaj oryginał (ang.)
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag. businesswire.com 2025-03-13 12:40:00 Czytaj oryginał (ang.)
Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15. businesswire.com 2025-02-06 09:51:00 Czytaj oryginał (ang.)
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. SHANGHAI , Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. prnewswire.com 2025-02-06 08:35:00 Czytaj oryginał (ang.)
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the anticipated Revlimid revenue drop, RDY's new product launches in biosimilars and GLP-1 segments are expected to offset losses, driving future growth. RDY's current P/E ratio of 17.7x is near historical lows; a conservative 23x PE, which is equal to the peer median and slightly lower than the median of the historical range. seekingalpha.com 2025-01-30 08:56:03 Czytaj oryginał (ang.)
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same. zacks.com 2025-01-24 14:11:09 Czytaj oryginał (ang.)
Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ET Company Participants Richa Periwal – Head-Investor Relations and Analytics Erez Israeli – Chief Executive Officer M V Narasimham – Chief Financial Officer Conference Call Participants Kunal Dhamesha – Macquarie Neha Manpuria – Bank of America Amey Chalke – JM Financial Bino Pathiparampil – Elara Capital Surya Narayan Patra – PhillipCapital Damayanti Kerai – HSBC Tushar Manudhane – Motilal Oswal Financial Services Saion Mukherjee – Nomura Foram Parekh – Bank of Baroda Capital Market Anubhav Agrawal – UBS Vishal Manchanda – Systematix Shashank Krishnakumar – Emkay Global Operator Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. seekingalpha.com 2025-01-23 17:58:51 Czytaj oryginał (ang.)
Dr. Reddy's Q3 & 9MFY25 Financial Results HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY25--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. businesswire.com 2025-01-23 14:35:00 Czytaj oryginał (ang.)
3 Emerging Market Stocks to Buy as 2024 Wraps Up Here, we have picked three emerging market stocks, QFIN, YTRA and RDY, which are expected to show robust growth in 2025 on their growth strategies and fundamentals. zacks.com 2024-12-13 14:06:08 Czytaj oryginał (ang.)
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable. zacks.com 2024-12-02 12:50:29 Czytaj oryginał (ang.)
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma. zacks.com 2024-11-29 13:10:16 Czytaj oryginał (ang.)
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India. businesswire.com 2024-11-28 08:15:00 Czytaj oryginał (ang.)
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market. businesswire.com 2024-11-26 10:07:00 Czytaj oryginał (ang.)
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets. zacks.com 2024-11-06 13:00:36 Czytaj oryginał (ang.)
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Kunal Dhamesha - Macquarie Neha Manpuria - Bank of America Amey Chalke - JM Financial Mikaela Franceschina - Barclays Harith Ahmad - Avendus Spark Damayanti Kerai - HSBC Bino Pathiparampil - Elara Capital Surya Patra - PhillipCapital Tarang Agarwal - Old Bridge Kunal Randeria - Axis Capital Anubhav Agarwal - UBS Vishal Manchanda - Systematix Operator Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. seekingalpha.com 2024-11-05 15:26:10 Czytaj oryginał (ang.)
Dr. Reddy's Q2 & H1FY25 Financial Results HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2024. businesswire.com 2024-11-05 11:59:00 Czytaj oryginał (ang.)
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanAssociationfortheAdvancementofScience--Dr. Reddy's has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science. businesswire.com 2024-10-25 11:40:00 Czytaj oryginał (ang.)
Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's launches comprehensive menopause support program and training for employees during menopause awareness month. businesswire.com 2024-10-14 13:47:00 Czytaj oryginał (ang.)
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma BENGALURU, India & HYDERABAD, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma. businesswire.com 2024-10-08 15:32:00 Czytaj oryginał (ang.)
Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries. businesswire.com 2024-10-02 15:10:00 Czytaj oryginał (ang.)
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2024-09-20 14:41:21 Czytaj oryginał (ang.)
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug. zacks.com 2024-08-21 16:00:59 Czytaj oryginał (ang.)
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy Dr. Reddy's Laboratories stock has risen 29% since my last publication, with additional tailwinds from legislative changes and strong business momentum. The company's enduring competitive advantage as a generics pharmaceutical manufacturer produces abnormally high and persistent returns on capital. Quarterly insights show growth in U.S. generics, Europe, and India markets, with high-quality economic characteristics supporting $107/share intrinsic value. seekingalpha.com 2024-08-13 05:33:47 Czytaj oryginał (ang.)
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India. zacks.com 2024-07-29 15:10:21 Czytaj oryginał (ang.)
Dr. Reddy's Q1FY25 Financial Results HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2024. businesswire.com 2024-07-27 13:51:00 Czytaj oryginał (ang.)
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide. zacks.com 2024-06-27 15:25:53 Czytaj oryginał (ang.)
Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Acquisition--Dr. Reddy's to acquire Nicotinell and related portfolio in significant step towards building global consumer healthcare business. businesswire.com 2024-06-26 15:26:00 Czytaj oryginał (ang.)
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities HYDERABAD, India--(BUSINESS WIRE)-- #Aurigene--Aurigene inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. businesswire.com 2024-06-03 17:05:00 Czytaj oryginał (ang.)